Phathom Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHAT research report →
Range $10 – $22
Price Chart
About the company
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada.
- CEO
- Steven L. Basta
- IPO
- 2019
- Employees
- 371
- HQ
- Florham Park, NJ, US
Get TickerSpark's AI analysis on PHAT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $378.82M
- P/E
- -5.34
- Fwd P/E
- 7.09
- PEG
- -0.03
- P/S
- 1.63
- P/B
- 0.00
- EV/EBITDA
- -21.72
- Div Yield
- 0.00%
- Gross Margin
- 80.68%
- Op Margin
- -9.26%
- Net Margin
- -30.19%
- ROE
- 29.66%
- ROIC
- -14.90%
Latest fiscal year · YoY change
- Revenue
- $175.11M+216.9%
- Gross Profit
- $152.51M+222.6%
- Op Income
- $-159,986,000
- Net Income
- $-221,247,000+33.8%
- EPS
- $-3.03+42.7%
- OCF Growth
- +37.5%
- FCF Growth
- +37.4%
- 52W High
- $18.31
- 52W Low
- $4.62
- 50D MA
- $6.69
- 200D MA
- $9.86
- Beta
- 0.50
- RSI (14)
- 31
- Avg Volume
- 1.45M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Phathom posted strong Q3 growth and its second straight quarter of operating profitability, while leaning harder into access initiatives to keep VOQUEZNA’s prescription momentum building into Q4 and 2027.· October 29, 2026
- Q3 net revenues were $84.7 million, up 71% year over year and 14% sequentially.
- The company reported positive operating profit of $5.8 million and cash from operations of about $2.1 million, both excluding stock-based compensation.
- About 380,000 VOQUEZNA prescriptions were filled in Q3; roughly 248,000 were covered and about 132,000 were cash pay.
- Management reaffirmed full-year 2026 revenue guidance of $310 million-$325 million and expects gross margin of about 80%.
- Access First and the BlinkRx channel, plus a new $0 copay program for eligible commercially insured patients, are central to the growth strategy.
Phathom reported Q3 net revenues of $84.7 million, up $35.2 million or 71% year over year and up $10.4 million or 14% sequentially. Cash operating expenses were $60.5 million, and operating profit was $5.8 million, both excluding stock-based compensation; cash generated from operations was about $2.1 million. Gross profit margin was approximately 78%, below guidance, due to certain one-time charges in cost of revenues. For the full year 2026, management reiterated revenue guidance of $310 million-$325 million, expects gross-to-net discount to come in toward the lower end of the 55%-59% range, gross margin to be approximately 80%, and cash operating expenses excluding stock-based compensation to be $235 million-$245 million. Management also said it continues to expect durable positive cash flow in 2027.
Steve Basta said the quarter showed ‘solid execution’ and emphasized that Phathom has materially strengthened its financial position over the past year and a half. He framed the main commercial challenge as not physician belief in VOQUEZNA’s efficacy, but making access, affordability, and prior authorization easier for offices and patients. He highlighted Access First, BlinkRx, and the new $0 copay offering as tools to improve prescription conversion and said the company believes it is positioned for a strong fourth quarter.
Sanjeev Narula said Q3 revenue growth was supported by strong covered prescription trends, with covered volume up about 19% sequentially. He said the gross-to-net discount came in slightly below guidance because of channel mix and lower wholesale inventory, while the gross margin miss versus guidance was primarily due to a one-time manufacturing charge. He also pointed to $184.6 million in cash and cash equivalents, the shift to a roughly $119 million cash holding requirement under the Revenue Interest Financing Agreement, and reiterated that current cash plus future operating cash generation should be sufficient to fund the business without another debt or equity raise.
Analysts focused heavily on whether Access First, BlinkRx, and the $0 copay program can meaningfully lift prescriptions and what that means for gross-to-net. Management said the issue is mostly ‘inertia’ rather than resistance, with physicians defaulting to local pharmacies; they believe educating offices and moving scripts to BlinkRx improves prior authorization, fill, and refill rates over time. Questions also centered on the pending FDA/GAIN Act litigation and competitor PCAB risk; management declined to predict legal next steps, said payer negotiations have not changed meaningfully, and argued that a second PCAB could actually expand category awareness and help the market leader. On the EoE program, management said top-line data from the first 12-week blinded phase is expected this quarter, with FDA discussions on next steps and possible pediatric exclusivity extension in 2027.
The call showed strong revenue growth, positive cash generation, and a second consecutive quarter of operating profitability, suggesting the business is scaling. Management believes Access First, BlinkRx, and the $0 copay offer can improve conversion and deepen adoption over time, while payer coverage is already broad with north of 80% of commercial lives covered. They also expressed confidence that a second PCAB launch could expand category awareness rather than slow VOQUEZNA’s growth.
Gross margin came in below guidance because of one-time manufacturing charges, and management acknowledged that access improvement is a gradual office-by-office process rather than an immediate fix. The company also faces ongoing litigation over VOQUEZNA exclusivity and a potential competitor PCAB launch, even though management said it has not yet seen meaningful payer disruption. Cash flow is improving, but management still expects durable positive cash flow only in 2027, so execution must continue to support the current valuation and growth plan.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.7%
- Shares Outstanding
- 81.29M
- Float Shares
- 65.57M
of shares held by institutions
173 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 12.47M | 0 |
| Medicxi Ventures Management (Jersey) Ltd | 7.46M | 0 |
| Blackrock, Inc. | 5.25M | ▲ 721.13K |
| Carlyle Group Inc. | 3.50M | 0 |
| Vanguard Group Inc | 3.18M | ▼ 38.36K |
| Vanguard Capital Management LLC | 2.74M | ▲ 78.17K |
| Franklin Templeton Inc | 2.41M | ▲ 435.56K |
| Millennium Management LLC | 2.40M | ▼ 974.86K |
| Gw&K Investment Management, LLC | 2.13M | ▼ 38.02K |
| 683 Capital Management, LLC | 2.00M | ▲ 150.00K |
| State Street Corp | 2.00M | ▲ 411.55K |
| Nea Management Company, LLC | 1.96M | 0 |
Held by 205 ETFs
Biggest fund positions in PHAT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | Narula Sanjeev | other | 13,485 |
| Sep 3, 26 | Breedlove Robert Charles | other | 460 |
| Jul 14, 26 | Breedlove Robert Charles | other | 1,555 |
| May 22, 26 | Parikh Asit | other | 28,000 |
| May 22, 26 | Parikh Asit | other | 28,000 |
| May 20, 26 | Parikh Asit | other | 17,500 |
| May 19, 26 | Parikh Asit | other | 24,122 |
| May 20, 26 | Parikh Asit | sell | 17,500 |
| May 19, 26 | Topper James N | other | 24,122 |
| May 19, 26 | Stenhouse Mark | other | 24,122 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PHAT coverage
Recent articles, reports, and earnings notes.
No research on PHAT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHAT report →Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously
globenewswire.com · Nov 19
Phathom: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 18
Implied Volatility Surging for Phathom Pharmaceuticals Stock Options
zacks.com · Nov 6
Phathom Pharmaceuticals to Participate in November Investor Conferences
globenewswire.com · Nov 4
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
globenewswire.com · Nov 3
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
marketbeat.com · Oct 29
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.